公开(公告)号：US06465020B1

公开(公告)日：2002-10-15

申请号：US09610322

申请日：2000-07-05

Applicant: Jun Cheon ,  Jejong Kim ,  Jungku Lee ,  Hankyeum Kim ,  Doogun Moon

Inventor： Jun Cheon ,  Jejong Kim ,  Jungku Lee ,  Hankyeum Kim ,  Doogun Moon

IPC: A61K3578

CPC classification number: A61K31/10 ,  A61K36/8962 ,  A61K36/9062

Abstract: This invention is concerned with the clinical investigation of the therapeutic effects of garlic extracts containing allicin, diallyl disulfide, and diallyl trisulfide. The intake of garlic or therapeutically active substances such as allicin from garlic, induces immunostimulation and these active substances possess strong antitumor effects including the apoptosis of tumors, including the programmed cell death of human prostatic and bladder tumor cells. This invention claims that garlic and/or garlic extracts possess very effective therapeutic substances useful not only to treat human prostate and bladder cancers to extend life span of patients, but also to suppress or prevent bladder and prostate gland cancers.

Abstract translation: 本发明涉及含有大蒜素，二烯丙基二硫化物和二烯丙基三硫化物的大蒜提取物的治疗效果的临床研究。 摄入大蒜或治疗活性物质如来自大蒜的大蒜素，诱导免疫刺激，并且这些活性物质具有强的抗肿瘤作用，包括肿瘤细胞凋亡，包括人前列腺和膀胱肿瘤细胞的程序性细胞死亡。 本发明要求大蒜和/或大蒜提取物具有非常有效的治疗物质，其不仅可用于治疗人类前列腺和膀胱癌以延长患者的寿命，而且可用于抑制或预防膀胱和前列腺癌。

公开(公告)号：US20050163855A1

公开(公告)日：2005-07-28

申请号：US11043069

申请日：2005-01-27

Applicant: Cheong Cho ,  Kyoung Kang ,  Sang Lee ,  Jeong Ku ,  Taekrho Kim ,  Sung Lee ,  Jae Choi ,  Jun Cheon ,  Tae An ,  Hyun Park ,  Eun Jeon ,  Kwang Choi ,  Jee Lim ,  Kwang Hong ,  Hyesuk Hong ,  Il Kim ,  Tae Kim ,  Nak Choi ,  Young Kim ,  Kyu Yeon ,  Hearan Suh ,  Hae Jin ,  Jinwan Kim ,  In Min

Inventor： Cheong Cho ,  Kyoung Kang ,  Sang Lee ,  Jeong Ku ,  Taekrho Kim ,  Sung Lee ,  Jae Choi ,  Jun Cheon ,  Tae An ,  Hyun Park ,  Eun Jeon ,  Kwang Choi ,  Jee Lim ,  Kwang Hong ,  Hyesuk Hong ,  Il Kim ,  Tae Kim ,  Nak Choi ,  Young Kim ,  Kyu Yeon ,  Hearan Suh ,  Hae Jin ,  Jinwan Kim ,  In Min

IPC: C07D409/04 ,  A61K9/16 ,  A61K9/20 ,  A61K31/497 ,  A61K31/724 ,  A61K9/14

CPC classification number: A61K9/1635 ,  A61K9/1652 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/497 ,  A61K31/724 ,  C07D409/04

Abstract: Provided is a method of preparing low-crystallinity oltipraz or amorphous oltipraz. The method includes: obtaining a mixed solution containing oltipraz and a water-soluble polymer or a water-insoluble polymer in a solvent, the solvent being an organic solvent or purified water; and solid-dispersing the oltipraz in the polymer. In the solid-dispersing, the mixed solution may be spray dried using a spray dryer or granulated using a fluid bed granulator.

Abstract translation: 提供制备低结晶度奥替普拉或无定形奥替普拉的方法。 该方法包括：在溶剂中得到含有奥替普拉和水溶性聚合物或水不溶性聚合物的混合溶液，溶剂为有机溶剂或纯化水; 并将奥替普拉固化在聚合物中。 在固体分散中，混合溶液可以使用喷雾干燥器喷雾干燥或使用流化床造粒机造粒。

公开(公告)号：US6159467A

公开(公告)日：2000-12-12

申请号：US10114

申请日：1998-01-21

Applicant: Leland W. K. Chung ,  Chinghai Kao ,  Robert A. Sikes ,  Song-Chu Ko ,  Jun Cheon

Inventor： Leland W. K. Chung ,  Chinghai Kao ,  Robert A. Sikes ,  Song-Chu Ko ,  Jun Cheon

IPC: A61K48/00 ,  C12N15/861 ,  C12P21/04 ,  A01N63/00 ,  C12N15/00

CPC classification number: C12N15/86 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2830/008 ,  C12N2830/85

Abstract: A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered intravascularly to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. Systemic administration of this agent provides a preferred route over previous disclosure of local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions, including benign prostatic hypertrophy and arteriosclerosis.

Abstract translation: 基于使用骨钙素启动子表达胸苷激酶的重组腺病毒的治疗剂可以血管内给药以治疗转移性癌症，包括骨肉瘤，乳腺癌，前列腺癌，眼黑素瘤或脑癌。 该药剂的系统性给药提供优于先前公开的局部直接给药的优选途径。 相同的治疗剂可以有效地用于良性病症的治疗，包括良性前列腺肥大和动脉硬化。

公开(公告)号：US06596534B1

公开(公告)日：2003-07-22

申请号：US09534414

申请日：2000-03-23

Applicant: Leland W. K. Chung ,  Chinghai Kao ,  Robert A. Sikes ,  Song-Chu Ko ,  Jun Cheon

Inventor： Leland W. K. Chung ,  Chinghai Kao ,  Robert A. Sikes ,  Song-Chu Ko ,  Jun Cheon

IPC: A01N6300

CPC classification number: C12N15/86 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2830/008 ,  C12N2830/85

Abstract: A therapeutic agent based on a recombinant adenovirus which employs an osteocalcin promoter for the expression of thymidine kinase can be administered intravascularly to treat metastatic cancer, including osteosarcoma, breast cancer, prostate cancer, ocular melanoma or brain cancer. Systemic administration of this agent provides a preferred route over previous disclosure of local direct administration. The same therapeutic agent can be effectively employed in the treatment of benign conditions, including benign prostatic hypertrophy and arteriosclerosis.

Abstract translation: 基于使用骨钙素启动子表达胸苷激酶的重组腺病毒的治疗剂可以血管内给药以治疗转移性癌症，包括骨肉瘤，乳腺癌，前列腺癌，眼黑素瘤或脑癌。 该药剂的系统性给药提供优于先前公开的局部直接给药的优选途径。 相同的治疗剂可以有效地用于良性病症的治疗，包括良性前列腺肥大和动脉硬化。

公开(公告)号：US20070122480A1

公开(公告)日：2007-05-31

申请号：US10574337

申请日：2004-09-25

Applicant: Seong Cho ,  Jeong Ku ,  Dong Lim ,  Jun Cheon ,  Tae An ,  Jae Ko ,  Yong Youn ,  Choong Park ,  Hea Suh ,  Eun Yang ,  Eun Jeon ,  Chang Kim

Inventor： Seong Cho ,  Jeong Ku ,  Dong Lim ,  Jun Cheon ,  Tae An ,  Jae Ko ,  Yong Youn ,  Choong Park ,  Hea Suh ,  Eun Yang ,  Eun Jeon ,  Chang Kim

IPC: A61K9/24

CPC classification number: A61K9/209

Abstract: Provided is a sustained-release formulation: (a) a sustained-release core including an active ingredient and a polymer having erosion and swelling property in mammalian intestinal secretions, (b) an enteric film coating layer coated on the sustained-release core, and (c) an active ingredient-containing film coating layer coated on the enteric film coating layer and including the active ingredient and hydrophilic polymer for film coating.

Abstract translation: 提供一种缓释制剂：（a）包含活性成分的缓释核心和在哺乳动物肠分泌物中具有侵蚀和溶胀性质的聚合物，（b）涂覆在缓释核心上的肠溶薄膜包衣层，以及 （c）涂覆在肠溶薄膜包衣层上的含活性成分的膜包衣层，并且包括活性成分和用于薄膜包衣的亲水性聚合物。

公开(公告)号：US5772993A

公开(公告)日：1998-06-30

申请号：US785088

申请日：1997-01-21

Applicant: Leland W. K. Chung ,  Chinghai Kao ,  Robert A. Sikes ,  Song-Chu Ko ,  Jun Cheon

Inventor： Leland W. K. Chung ,  Chinghai Kao ,  Robert A. Sikes ,  Song-Chu Ko ,  Jun Cheon

IPC: A61K48/00 ,  C12N15/861 ,  C12P21/04 ,  A01N63/00 ,  C12N15/00

CPC classification number: C12N15/86 ,  A61K48/00 ,  C12N2710/10343 ,  C12N2710/10345 ,  C12N2830/008 ,  C12N2830/85

Abstract: A recombinant adenovirus Ad-OC-TK was constructed, with cell specific gene expression, which contains osteocalcin (OC) promoter that drives the expression of herpes simplex virus thymidine kinase (TK); the addition of acyclovir (ACV), a pro-drug for the inhibition of cell proliferation, to Ad-OC-TK resulted in the induction of osteoblast-specific cell death in vitro. The Ad-OC-TK virus plus ACV treatment is highly selective in blocking the growth of both murine and human osteosarcoma cell lines in vitro and murine osteosarcoma in vivo.

Abstract translation: 构建了重组腺病毒Ad-OC-TK，其具有细胞特异性基因表达，其含有驱动单纯疱疹病毒胸苷激酶（TK）表达的骨钙素（OC）启动子; 将用于抑制细胞增殖的前体药物阿昔洛韦（ACV）添加到Ad-OC-TK导致体外诱导成骨细胞特异性细胞死亡。 Ad-OC-TK病毒加ACV治疗在体外阻断鼠和人类骨肉瘤细胞系的生长和体内鼠骨肉瘤的高度选择性。